Suppr超能文献

针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白的四重适体设计

design of quadruplex aptamers against the spike protein of SARS-CoV-2.

作者信息

Behbahani Mandana, Mohabatkar Hassan, Hosseini Barumand

机构信息

Department of Biotechnology, Faculty of Biological Science and Technology, University of Isfahan, Hezar Jareeb St., Isfahan, 81746-73441, Iran.

出版信息

Inform Med Unlocked. 2021;26:100757. doi: 10.1016/j.imu.2021.100757. Epub 2021 Oct 14.

Abstract

Nucleic acid aptamers are short sequences of nucleic acid ligands that bind to a specific target molecule. Aptamers are experimentally nominated using the well-designed SELEX (systematic evolution of ligands by exponential enrichment) method. Here, we designed a new method for diagnosis and blocking SARS-CoV-2 based on G-quadruplex aptamer. This aptamer was developed against the receptor-binding domain (RBD) region of the spike protein. In the current study, ten quadruplex DNA aptamers entitled AP1, AP2, AP3, AP4, AP5, AP6, AP7, AP8, AP9, and AP10 were designed and had high HADDOCK scores. One quadruplex aptamer sequence (AP1) was selected based on the interaction with RBD of SARS-CoV-2. Results showed that AP1 aptamer could be used as an agent in the diagnosis and therapy of SARS-CoV-2, although more works are still needed.

摘要

核酸适配体是与特定靶分子结合的核酸配体短序列。适配体通过精心设计的SELEX(指数富集配体系统进化)方法经实验筛选获得。在此,我们基于G-四链体适配体设计了一种用于诊断和阻断新型冠状病毒的新方法。这种适配体是针对刺突蛋白的受体结合域(RBD)区域开发的。在本研究中,设计了十种名为AP1、AP2、AP3、AP4、AP5、AP6、AP7、AP8、AP9和AP10的四链体DNA适配体,它们具有较高的HADDOCK评分。基于与新型冠状病毒RBD的相互作用,选择了一种四链体适配体序列(AP1)。结果表明,AP1适配体可作为新型冠状病毒诊断和治疗的一种试剂,尽管仍需要更多的研究工作。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa0e/8514331/a159d90af73e/gr1_lrg.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验